BIOLASE (NASDAQ:BIOL) Reports Pricing of $14.4 Million Bought Deal Offering

BIOLASE, Inc. (NASDAQ:BIOL) reported that the company has entered into an underwriting deal with Maxim Group LLC under which the underwriters have agreed to purchase, on a firm commitment basis, 14,000,000 shares of common stock of the Company, at a price to the public of $1.03 per share less underwriting discounts and commissions..  The gross proceeds from the offering are expected to be approximately $14.4 million, before deducting underwriting discounts and commissions and estimated offering expenses

This offering is expected to close on or about February 10, 2021, subject to satisfaction of customary closing conditions. Maxim Group LLC, The Benchmark Company, LLC & Colliers Securities LLC are acting as joint-bookrunning managers for the offering.


The shares of common stock are being offered pursuant to a shelf registration statement on Form S-3 (File No. 333-233172) previously filed and declared effective by the Securities and Exchange Commission (SEC). A prospectus supplement will be filed with the SEC and will form a part of the effective registration statement. Copies of the prospectus supplement and accompanying prospectus relating to the public offering may be obtained, when available, by contacting Maxim Group LLC, 405 Lexington Avenue, 2nd Floor, New York, NY 10174, or by telephone at (212) 895-3745.

This press release does not constitute an offer to sell or the solicitation of an offer to buy, nor will there be any sales of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction.

Leave a Reply

Your email address will not be published. Required fields are marked *